News & Events
Insight Genetics CEO Eric Dahlhauser participated in the panel "Found in Translation: An Academia-Pharma Match-Up Sees Success" at the 2015 BIO International Convention on June 16, 2015.
The panel focused on the challenges of translating basic academic research into commercially viable products. Insight Genetics and Vanderbilt University Medical Center were highlighted as a success story for their combined work on advancing diagnostics options for subtyping Triple Negative Breast Cancer (TNBC).
After taking an exclusive license to Vanderbilt’s TNBC subtyping technology, Insight Genetics and Vanderbilt’s Pietenpol laboratory continue collaborative research aimed at further defining the molecular drivers of the various TNBC subtypes. Insight Genetics has both improved the original subtyping algorithm and made it commercial-ready (Insight TNBCtype™).
Dahlhauser was joined on the panel by Hassan Naqvi, licensing officer at Vanderbilt University Center for Technology Transfer and Commercialization. Additional participants included Anthony Coyle, vice president and chief scientific officer for the Centers for Therapeutic Innovation at Pfizer, and Kathleen Denis, associate vice president of technology transfer at Rockefeller University. The panel will be moderated by New York University’s, Director of Life Sciences Technology Transfer, Sadhana Chitale.